Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › warfarin

warfarin

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of warfarin

70 trials tracked of warfarin: 31 in phase 3 or 4 and 10 with published results. The most-cited published study has 440 citations.

70Trials tracked
31Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 12 Phase 3 19 Phase 2 12 Phase 1 10 Other / NA 17
  1. Phase 4 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) Completed · 440 cited
  2. Phase 3 A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT) Completed · 311 cited
  3. Phase 3 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) Completed · 248 cited
  4. Phase 4 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed · 230 cited
  5. Phase 3 Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy Completed · 132 cited
  6. Phase 4 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed · 46 cited
Show 44 more trials
  1. Phase 3 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation Completed · 32 cited
  2. Phase 3 Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Completed · 22 cited
  3. Phase 4 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation Completed · 15 cited
  4. Phase 3 Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation Completed · 9 cited
  5. Phase 4 A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir) Completed
  6. Phase 4 Clinical and Economic Implications of Genetic Testing for Warfarin Management Completed
  7. Phase 4 Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy Completed
  8. Phase 4 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium Completed
  9. Phase 4 A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Completed
  10. Phase 4 Treatment of Upper Extremity Deep-Vein Thrombosis Completed
  11. Phase 4 Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy Completed
  12. Phase 4 Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers Completed
  13. Phase 3 AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients Completed
  14. Phase 3 Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus Completed
  15. Phase 3 WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation Completed
  16. Phase 3 Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer Completed
  17. Phase 3 Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial Completed
  18. Phase 3 Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Completed
  19. Phase 3 Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) Completed
  20. Phase 3 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed
  21. Phase 3 Secondary Prevention of Venous Thrombo Embolism (VTE). Completed
  22. Phase 3 Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation Completed
  23. Phase 3 Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate Completed
  24. Phase 3 An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation Completed
  25. Phase 3 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed
  26. Phase 2 PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin Completed
  27. Phase 2 Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients Completed
  28. Phase 2 Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection Completed
  29. Phase 2 Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices Completed
  30. Phase 2 A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin Completed
  31. Phase 2 A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis Completed
  32. Phase 2 Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin Completed
  33. Phase 2 Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation Completed
  34. Phase 2 A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation Completed
  35. Phase 2 A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation Completed
  36. Phase 2 Sunitinib or Cediranib for Alveolar Soft Part Sarcoma Completed
  37. Phase 2 Odiparcil For The Prevention Of Venous Thromboembolism Completed
  38. Phase 1 The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin Completed
  39. Phase 1 A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants Completed
  40. Phase 1 A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants Completed
  41. Phase 1 Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin Completed
  42. Phase 1 Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin Completed
  43. Phase 1 A Study of LY2216684 and Warfarin in Healthy Subjects Completed
  44. Phase 1 Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers Completed

Showing the 50 most-cited and recently-updated of 70 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
DOACs reduce thrombosis recurrence and major bleeding compared to warfarin in morbidly obese VTE patients
Diabetes & Endocrinology Meta-analysis
DOACs reduce thrombosis recurrence and major bleeding compared to warfarin in morbidly obese VTE patients DOACs Show Lower Risk of Blood Clots in Patients with Obesity
This meta-analysis of 44,672 patients found that DOACs are associated with lower risks of thrombosis recurrence (OR 0.74) and major bleeding…
New data suggests that direct acting oral anticoagulants may be more effective than warfarin for managing blood clots in patients with morbi…
NEJM Aug 22, 2026
Thromboembolic events cost 2.5-fold more per event than bleeding after high-risk endoscopy
Gastroenterology RCT
Thromboembolic events cost 2.5-fold more per event than bleeding after high-risk endoscopy High Risk Endoscopy Procedures Linked to Bleeding in Patients
This retrospective cohort study of 2,486 adults on DOAC or warfarin undergoing high-risk endoscopy found a 22.9% bleeding rate at 90 days an…
Patients with atrial fibrillation undergoing high-risk endoscopy face significant risks of bleeding and stroke, which can lead to high medic…
medRxiv Aug 4, 2026
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
Drug Pipeline Guideline
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Frontiers Jun 13, 2026
Left atrial appendage occlusion and NOACs reduce mortality compared with warfarin in atrial fibrillation
Cardiology Meta-analysis
Left atrial appendage occlusion and NOACs reduce mortality compared with warfarin in atrial fibrillation LAAO, low-dose NOACs beat warfarin for atrial fibrillation survival
A network meta-analysis compared left atrial appendage occlusion (LAAO), low-dose NOACs, standard-dose NOACs, and warfarin in non-valvular a…
For people with atrial fibrillation, warfarin may be the worst option for survival. New analysis finds LAAO and NOACs outperform it.
Jun 1, 2026
Meta-analysis finds lower bleeding risk with apixaban and rivaroxaban vs VKAs in dialysis patients with AF
Cardiology Meta-analysis
Meta-analysis finds lower bleeding risk with apixaban and rivaroxaban vs VKAs in dialysis patients with AF New Blood Thinners Cut Bleeding Risk For Dialysis Patients
This meta-analysis of observational studies and RCTs compared apixaban or rivaroxaban with vitamin K antagonists in dialysis patients with a…
New blood thinners could save lives for dialysis patients by cutting bleeding and stroke risks while waiting for bigger studies to confirm t…
May 14, 2026
DOACs versus VKAs for left ventricular thrombus management in adults
Cardiology Meta-analysis
DOACs versus VKAs for left ventricular thrombus management in adults Newer Blood Thinners May Be Safer for Heart Clot Patients
A meta-analysis suggests DOACs may be a reasonable alternative to VKAs for left ventricular thrombus, with similar efficacy and potentially …
If you have a blood clot in your heart, newer blood thinners may be just as effective as warfarin with a lower risk of dangerous bleeding.
Frontiers May 14, 2026
LAAC and DOACs match warfarin for stroke prevention in AF patients
Cardiology Meta-analysis
LAAC and DOACs match warfarin for stroke prevention in AF patients LAAC and DOACs Cut Bleeding Risk Better Than Warfarin
A network meta-analysis of 78,594 AF patients found LAAC and DOACs offered similar protection against ischemic stroke as warfarin, while sig…
New research shows two new options for atrial fibrillation patients lower bleeding risks while keeping stroke protection the same as older d…
medRxiv May 11, 2026
Proof of concept study uses preSCRIPT framework to annotate prescriptions in UK Biobank
Genetics & Precision Medicine
Proof of concept study uses preSCRIPT framework to annotate prescriptions in UK Biobank preSCRIPT framework identifies genetic links to drug response in UK Biobank
This proof of concept study utilized the preSCRIPT framework to filter and annotate raw prescription data from the UK Biobank, which include…
A proof of concept study in the UK Biobank used preSCRIPT to find genetic links to how people respond to common medications like warfarin an…
medRxiv Apr 30, 2026
Shorter fibrin clot lysis time linked to higher bleeding risk in atrial fibrillation patients on anticoagulants
Cardiology RCT
Shorter fibrin clot lysis time linked to higher bleeding risk in atrial fibrillation patients on anticoagulants Short clot breakdown time predicts higher bleeding risk
This RCT in 1,841 atrial fibrillation patients found that shorter pretreatment fibrin clot lysis time was associated with a significantly hi…
A simple blood test measuring how fast clots dissolve could help doctors spot patients at higher risk of bleeding before they even start tak…
Apr 22, 2026
Network meta-analysis compares prophylactic anticoagulants for central venous catheter-related thrombosis in cancer patients
Drug Pipeline Meta-analysis
Network meta-analysis compares prophylactic anticoagulants for central venous catheter-related thrombosis in cancer patients Cancer Patients May Avoid Clots With Safer Blood Thinner
This network meta-analysis synthesizes data from 19 clinical studies regarding prophylactic anticoagulation in cancer patients with central …
A new analysis shows one specific blood thinner may protect cancer patients from dangerous clots with fewer side effects.
Frontiers Apr 19, 2026
Narrative review examines left atrial appendage closure for stroke prevention in atrial fibrillation
Cardiology Sys. Review
Narrative review examines left atrial appendage closure for stroke prevention in atrial fibrillation The Tiny Ear-Shaped Pouch in Your Heart That Could Cause a Stroke
This narrative review evaluates left atrial appendage (LAA) closure as an alternative to warfarin, aspirin, or DOAC therapy for adults with …
A small heart implant seals off a stroke-risk pouch for atrial fibrillation patients who can't safely take blood thinners, with success rate…
Frontiers Apr 18, 2026
Regular antithrombotic use associated with increased nonbiliary pancreatitis risk in UK Biobank cohort
Gastroenterology Cohort
Regular antithrombotic use associated with increased nonbiliary pancreatitis risk in UK Biobank cohort Large UK study finds link between blood-thinning drugs and pancreatitis risk
A prospective cohort study of 431,754 UK Biobank participants found regular antithrombotic drug use was associated with a 31% increased risk…
Regular blood-thinning drug use is linked to a 31% higher risk of a specific pancreatitis type, with clopidogrel showing the strongest conne…
medRxiv Apr 8, 2026

All warfarin Articles